Atrial Fibrillation Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Abbott, Sanofi, Biotronik, Inc., Bristol-Myers Squibb, Novartis, AbbVie

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atrial Fibrillation pipeline constitutes 15+ key companies continuously working towards developing 15+ Atrial Fibrillation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Atrial Fibrillation Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atrial Fibrillation Market.

The Atrial Fibrillation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Atrial Fibrillation Pipeline Report: https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Atrial Fibrillation treatment therapies with a considerable amount of success over the years.
• Atrial Fibrillation companies working in the treatment market are Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others, are developing therapies for the Atrial Fibrillation treatment
• Emerging Atrial Fibrillation therapies such as - Research programme: , CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others are expected to have a significant impact on the Atrial Fibrillation market in the coming years.
• In December 2023, Efficacy and safety of the oral FXIa inhibitor Asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke (OCEANIC-AF) have been compared in a multicenter, international, randomised, active comparator-controlled, double-blind, double-dumy, parallel-group, 2-arm, Phase 3 study
• In March 2021, The ReVeRA trial, a Phase II proof-of-concept study using etripamil nasal spray to lower ventricular rate in patients having AF and rapid ventricular rate (AFib-RVR), was announced by Milestone Pharmaceuticals to have enrolled its first patient
• In January 2020, "Multicenter, Randomised, Active Comparatorcontrolled, Double-blind, Double-dumy, Parallel Group, Dose-finding Phase 2 Study to Compare the Safety of the Oral FXIaInhibitor BAY2433334 to Apixaban in Patients With Atrial Fibrillation" is the name of the PACIFIC-AF trial that Bayer started

Atrial Fibrillation Overview
Atrial Fibrillation (AF) is an irregular or trembling heartbeat that raises the risk of blood clots, stroke, heart failure, and other issues related to the heart. The heart's two upper chambers (the atria) and two lower chambers (the ventricles) beat chaotically and irregularly when atrial fibrillation is present.

Get a Free Sample PDF Report to know more about Atrial Fibrillation Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Atrial Fibrillation Drugs Under Different Phases of Clinical Development Include:
• Research programme: Thryv Therapeutics Inc.
• CTP-Amio: Vivasc Therapeutics
• Abelacimab: Anthos Therapeutics, Inc.
• Etripamil: Milestone Pharmaceuticals
• GENCARO: ARCA biopharma
• VE 1902: Verseon
• HBI-3000: HUYA Bioscience
• HSY 244: Novartis
• AGN-151607: AbbVie
• Asundexian: Bayer AG
• Inrhythm: InCarda Therapeutics, Inc.

Route of Administration
Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal antibody
• Small molecule
• Peptide

Atrial Fibrillation Pipeline Therapeutics Assessment
• Atrial Fibrillation Assessment by Product Type
• Atrial Fibrillation By Stage and Product Type
• Atrial Fibrillation Assessment by Route of Administration
• Atrial Fibrillation By Stage and Route of Administration
• Atrial Fibrillation Assessment by Molecule Type
• Atrial Fibrillation by Stage and Molecule Type

DelveInsight's Atrial Fibrillation Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Atrial Fibrillation product details are provided in the report. Download the Atrial Fibrillation pipeline report to learn more about the emerging Atrial Fibrillation therapies at:
https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Atrial Fibrillation Therapeutics Market include:
Key companies developing therapies for Atrial Fibrillation are - Boston Scientific Corporation, Medtronic, AtriCure, Inc, Johnson & Johnson (Biosense Webster, Inc.), BOEHRINGER INGELHEIM GMBH, CardioFocus, Abbott, Sanofi, Biotronik, Inc., Bristol-Myers Squibb, and others.

Atrial Fibrillation Pipeline Analysis:
The Atrial Fibrillation pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Atrial Fibrillation with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
• Atrial Fibrillation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Atrial Fibrillation drugs and therapies-
https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Atrial Fibrillation Pipeline Market Drivers
• Rising prevalence of Atrial fibrillation, increase in the Adoption of Advanced Technologies are some of the important factors that are fueling the Atrial Fibrillation Market.

Atrial Fibrillation Pipeline Market Barriers
• However, Complications associated with the use of Atrial fibrillation drugs, lack of awareness regarding medical therapy in underdeveloped and developing regions and other factors are creating obstacles in the Atrial Fibrillation Market growth.

Scope of Atrial Fibrillation Pipeline Drug Insight
• Coverage: Global
• Key Atrial Fibrillation Companies: Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others
• Key Atrial Fibrillation Therapies: Research programme: , CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others
• Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies
• Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers

Request for Sample PDF Report for Atrial Fibrillation Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Atrial Fibrillation Report Introduction
2 Atrial Fibrillation Executive Summary
3 Atrial Fibrillation Overview
4 Atrial Fibrillation- Analytical Perspective In-depth Commercial Assessment
5 Atrial Fibrillation Pipeline Therapeutics
6 Atrial Fibrillation Late Stage Products (Phase II/III)
7 Atrial Fibrillation Mid Stage Products (Phase II)
8 Atrial Fibrillation Early Stage Products (Phase I)
9 Atrial Fibrillation Preclinical Stage Products
10 Atrial Fibrillation Therapeutics Assessment
11 Atrial Fibrillation Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Atrial Fibrillation Key Companies
14 Atrial Fibrillation Key Products
15 Atrial Fibrillation Unmet Needs
16 Atrial Fibrillation Market Drivers and Barriers
17 Atrial Fibrillation Future Perspectives and Conclusion
18 Atrial Fibrillation Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Atrial Fibrillation Market https://www.delveinsight.com/report-store/atrial-fibrillation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Atrial Fibrillation-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Atrial Fibrillation Epidemiology https://www.delveinsight.com/report-store/atrial-fibrillation-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Atrial Fibrillation Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting/asset-prioritizaton-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.